A

Alliance Clinical Research of Tampa | Tampa, FL

Research site
(Unclaimed)
Location
8313 W Hillsborough Avenue Suite 210, Tampa, Florida, United States of America

Site insights

Top conditions

Top treatments

PF 06826647
Mirikizumab
GLPG3667
IMG-007
Favipiravir
PF-06480605
PF-06700841
Orismilast
PF-06826647
PL-8177

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 9 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Enrolling
Systemic Lupus Erythematosus
Drug: GLPG3667
Drug: Placebo

The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.

Active, not recruiting
Alopecia Areata (AA)
Drug: IMG-007

The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get...

Enrolling
Ulcerative Colitis Flare
Ulcerative
Drug: PL8177 Placebo
Drug: PL8177

This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermati...

Active, not recruiting
Atopic Dermatitis
Skin Diseases
Drug: Placebo
Drug: Orismilast modified release tablets

Trial sponsors

Pfizer logo
A
G
I
Lilly logo
P
Roche logo
UNION Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems